Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993;82:2714–18.10.1182/blood.V82.9.2714.2714
Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies. Blood 2006;108:922–7.10.1182/blood-2006-01-009803
Lau LG, Chng WJ, Liu TC. Transfusion medicine illustrated: unnecessary transfusions due to pseudothrombocytopenia. Transfusion 2004;44:801.10.1111/j.1537-2995.2004.04009.x
Braester A. Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia. Eur J Haematol 2003;70:251–2.10.1034/j.1600-0609.2003.00033.x
Smith ME, Reid DM, Jones CE, Jordan JV, Kautz CA, Shulman NR. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 1987;79:912–17.10.1172/JCI112901
Mueller-Eckhardt C, Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transf Med Rev 1990;4:69–77.10.1016/S0887-7963(90)70249-0
Asvadi P, Ahmadi Z, Chong BH. Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 2003;102:1670–7.10.1182/blood-2002-07-217512738668
Honda S, Tomiyama Y, Aoki T, et al. Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. Blood 1998;92:3675–83.10.1182/blood.V92.10.3675
Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071–6.10.1182/blood.V100.6.2071
Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002;99:2054–9.10.1182/blood.V99.6.205411877279
Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 2004;44:1033–40.10.1111/j.1537-2995.2004.03378.x15225244
Leach MF, Cooper LK, AuBuchon JP. Detection of drug-dependent antibodies by use of solid-phase red cell adherence techniques. Immunohematology 1995;11:143–9.10.21307/immunohematology-2019-806
Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81–8.10.1172/JCI1169872937378282825
Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood 2009;113:4970–6.10.1182/blood-2008-08-17306219109231
Christie DJ, Weber RW, Mullen PC, Cook JM, Aster RH. Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets. J Lab Clin Med 1984;104:730–40.
Leach MF, AuBuchon JP, Szczepiorkowski ZM. The incidence of positive direct antiglobulin tests and red cell drug antibodies in patients with drug-induced thrombocytopenia. Transfusion 2005;45:134A.